4. Verona’s Ohtuvayre (ensifentrine) for COPD Just as Verona Pharma secured the FDA nod to market inhalable COPD drug Ohtuvayre in June, its commercial prospects seemed to improve markedly. While ...

LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) held its annual analyst day on December 10 ...

Ligand Pharmaceuticals Incorporated will host its Investor and Analyst Day in Boston today. The event will feature presentations from Ligand CEO Todd Davis, CFO Tavo Espinoza, and other members of the ...

The FDA approved ensifentrine (Ohtuvayre; Verona) for COPD in June. It is a phosphodiesterase-3 and phosphodiesterase-4 inhibitor indicated for maintenance treatment of COPD in adults.₁₁ Two ...

This impressive performance was largely driven by $10.1 million in milestone payments, attributed to the FDA approvals of Ohtuvayre and Capvaxive, as well as the conditional marketing approval of ...

This impressive performance was largely driven by $10.1 million in milestone payments, attributed to the FDA approvals of Ohtuvayre and Capvaxive, as well as the conditional marketing approval of ...

Ensifentrine was approved on June 26, so this is its first full quarter of launch. Branded as Ohtuvayre, the FDA label had no surprises and no boxed warnings or REMS. The FDA label simply said ...

This strong performance was partly attributed to $10.1 million in milestone payments, which were linked to FDA approvals of Ohtuvayre and Capvaxive, as well as the conditional marketing approval of ...